🔗 Share this article

Given that the United States proceeds with historic revisions to its vaccine guidelines, an unexpected name has surfaced somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who first made her name by expressing skepticism about COVID-19 vaccinations in the pandemic and has focused upon potential fatalities following Covid immunization in her recent tenure at the FDA.

Scheduled Overhauls to Pediatric Immunization Schedule

Public health authorities were set to unveil sweeping revisions to the pediatric immunization program in December, bringing the US with Denmark’s immunization schedule, according to reports – a significant shift that would place the US out of step with many the global community with little proof for benefit. The planned update has been pushed back until the next year.

Instead of Vinay Prasad, Tracy Beth Høeg is set to speak at the gathering. She was recently named acting director of the FDA’s drug evaluation center, the fifth person to lead the center this calendar year.

Consolidating Power at the FDA

This interim role could signify a strengthened alliance between the drug and vaccine centers as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it points to a greater focus upon reevaluating previously authorized vaccines at the FDA.

The new acting director has frequently advocated for halting specific childhood vaccine recommendations in the US to become more like Denmark's approach, a country with comprehensive healthcare and a number of inhabitants approximately the size of the state of Wisconsin.

So far comments, she has continued to focus on vaccination policy – traditionally the domain of Dr. Prasad, chief of the FDA’s CBER – as opposed to drug regulation.

Doubts Over Background

The appointee has little discernible track record in pharmaceutical research, approval processes or administrative roles, which has been customary for previous leaders of the biologics center. She has been employed at the FDA as a key advisor to the agency head and the vaccine center since March.

“She appears not to have any of the qualifications” for overseeing the pharmaceutical oversight division, remarked Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in running a major agency. She has no expertise in pharmaceutical oversight.”

Previous heads of the center would “grasp laws and regulations and the underlying principles of pharmaceutical innovation”, noted a former acting FDA commissioner. “Frankly, she has not acquired the kind of background that prior appointees who headed the center have had.”

This division has an immense range of responsibilities at the agency, the former commissioner stated.

“Many people just zeroes in on the novel medication approvals, but the off-patent medication office approves a multitude of generic medications. There is also a biosimilars division, OTC medication office and so forth, and every single one need to be looked after,” Dr. Woodcock noted. “The responsibility you overlook, that’s the thing that I always told people is going to bite you.”

Furthermore, a substantial leadership aspect to the role, which manages over 5,000 personnel. “It’s a massive management job, if you execute it properly,” she said.

Agency Reaction and Controversial Programs

Regarding questions about Høeg’s qualifications and whether this assignment represents greater collaboration among agency officials on vaccines, a spokesperson responded that the “questions stem from inaccurate presumptions”.

“This background aligns with the duties of her position,” the spokesperson stated, citing the period Dr. Høeg spent guiding the FDA commissioner on “medication safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Høeg assumes responsibility for the agency head's controversial expedited review system, a controversial rapid medication authorization process that reportedly concerned her former heads. “How are these therapies being selected for this voucher program? Who is making the choices?” Dr. Howard said. “There is a lot of confidentiality occurring at the FDA right now.”

Broadly speaking, he said, “the Food and Drug Administration looks to be trending towards more relaxed rules of all drugs, with the exception of immunizations.”

Documented Track Record on Vaccines

Regarding vaccines, Høeg has a clearer, if troubling, history, Howard observe. She authored a study using non-validated volunteer-provided data to estimate the frequency of myocarditis following COVID-19 immunization. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have altered data to imply COVID-19 vaccinations are riskier than they are.

Included in her “wish list” for the incoming administration encompassed altering guidelines for new vaccines and discontinuing “unnecessary” vaccines, she remarked following the vote on a online show. At the FDA, Dr. Høeg has reportedly floated the idea of barring young men from obtaining COVID-19 vaccines.

“She’s an complete ideologue who begins with her conclusions and reverse-engineers to retrofit the data in a very disingenuous, dishonest manner,” Howard said.

Gaining Influence and a “Push for Payback”

Høeg became part of other dissenters, {like|